Company intelligence
Migration Biotherapeutics Limited
Trapping Cancer: Guiding Cells, Rapidly Transforming Health
Biotechnology Research
Cardiff, GB
4 employees
Founded 2020
5 public signals
About Migration Biotherapeutics Limited
Our ALIGHT(TM) technology helps neurosurgeons who want to provide patients with a better outcome than at most 18 months survival current average. By counteracting the spread of tumour-maintaining cells which ‘hitch-hike’ rapidly through healthy tissue and by giving existing treatments a better chance to take on the cancer without trading off quality of life.
Verified activity
Signals from Migration Biotherapeutics Limited
5 published signals
Presence & Recognition
Migration Biotherapeutics Limited hosted Peter Bannister and Davide Danovi at the Migration Biotherapeutics stand and afternoon talks session.
Reported by Davide Danovi
Presence & Recognition
Migration Biotherapeutics Limited showcased Davide Danovi with Padmini Krishnadas Liam Wright and the team of experts in Teddington as part of the National Physical Laboratory (NPL) Innovation Summit.
Reported by Peter Bannister
Research & Knowledge
Migration Biotherapeutics Limited received congratulations from King's College London, Anglia Ruskin University, The Brain Tumour Charity, and Cambridge Stem Cell Institute for Milandeep Kaur and Eve Charnley defending their MSc theses.
Reported by Migration Biotherapeutics Limited
People
Migration Biotherapeutics Limited appointed CSO Davide Danovi to join the Founders Spotlight Session chaired by Ilana Wisby.
Reported by Migration Biotherapeutics Limited
Partnerships
Migration Biotherapeutics Limited and National Physical Laboratory (NPL) have collaborated to develop a materials-based platform to treat lethal cancers including Glioblastoma.
Reported by Migration Biotherapeutics Limited